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The bioactive phospholipid lysophosphatidic acid (LPA)
and its receptors LPA1-3 are aberrantly expressed in
many types of human cancer. LPA has been reported to
induce tumor cell proliferation, migration, and cyto-
kine production. However, whether LPA exerts an effect
on lymphatic endothelial cells (LECs) or on lymphan-
giogenesis, a process of new lymphatic vessel formation
that is associated with increased metastasis and poor
prognosis in cancer patients, has been unknown. Here,
we show that LPA induces cell proliferation, survival,
migration, and tube formation, and promotes lymphan-
giogenesis in vitro in human dermal LECs. In addition,
LPA induces IL-8 expression by enhancing IL-8 pro-
moter activity via activation of the NF-B pathway in
LECs. Using IL-8 siRNA and IL-8 neutralizing antibody,
we revealed that IL-8 plays an important role in LPA-
induced lymphangiogenesis in vitro. Moreover, using
siRNA inhibition, we discovered that LPA-induced lym-
phangiogenesis in vitro and IL-8 production are medi-
ated via the LPA2 receptor in LECs. Finally, using human
sentinel afferent lymphatic vessel explants, we demon-
strated that LPA up-regulates IL-8 production in the LECs
of lymphatic endothelia. These studies provide the first
evidence that LPA promotes lymphangiogenesis and in-
duces IL-8 production in LECs; we also reveal a possible
newroleof LPA in thepromotionof tumorprogression, as
well asmetastasis, in different cancer types. (Am J Pathol
2012, 180:2170–2181; DOI: 10.1016/j.ajpath.2012.03.003)
The bioactive phospholipid lysophosphatidic acid (LPA)
has been reported to induce tumor cell proliferation, mi-
2170gration, cytokine production, metastasis, and angiogen-
esis.1 LPA binds to specific G protein-coupled receptors
(LPA1–6) to influence cell behavior.
1 Among these recep-
tors, the endothelial differentiation gene (EDG) G protein-
coupled receptor subfamily (EDG2/LPA1, EDG4/LPA2,
and EDG7/LPA3) are the most widely expressed and best
characterized.2 The majority of extracellular LPA is pro-
duced by autotaxin (ATX) from lysophosphatidylcholine;
ATX is a secreted lysophospholipase-D initially identified
from melanoma cell lines3, and lysophosphatidylcholine
is the most abundant phospholipid.4 Although low in nor-
mal plasma and tissues, LPA levels have been shown to
be elevated in malignant effusions of patients with ovar-
ian cancer.5 Overall, LPA receptors have been shown to
be highly expressed in several human cancers, including
ovarian, endometrial, cervical, breast, and gastric can-
cers and multiple myeloma.6–8
Lymphangiogenesis is a complex process of new lym-
phatic vessel formation that requires coordination of lym-
phatic endothelial cell (LEC) proliferation, migration, and
tube-like network formation. In the adult, the quiescent
LECs in lymphatic vasculature undergo lymphangiogen-
esis during tissue repair or regeneration or in pathologi-
cal conditions, including tumor growth and metastasis
and tumor-associated severe ascites.9–12 Tumor-in-
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tumor cells to the regional lymph nodes via the afferent
lymphatic vessels, thus establishing a preferred route for
lymphatic metastases in many solid tumors; indeed, tu-
mor-induced lymphangiogenesis has been associated
with increased metastasis and poor prognosis in cancer
patients.10 Although several lymphangiogenic growth
factors,13 including vascular endothelial growth factors
VEGF-A, VEGF-C, and VEGF-D and fibroblast growth fac-
tor 2 (FGF-2),14 have been recognized in recent years,
the molecular and cellular regulation of lymphangiogen-
esis is still largely unknown.
Previous studies suggest a possible role of the ATX-
LPA axis in lymphangiogenesis. LPA1 knockdown re-
sulted in lymphatic vessel malformation in zebrafish, sug-
gesting that LPA1 is necessary for embryonic lymphatic
vessel development.15 In a study using specimens from
patients with gastric cancer, LPA2 expression correlated
with increased lymphatic invasion, venous invasion, and
lymph node metastasis.8 In mice, ATX was essential for
vascular development through the production of LPA.16
In an in vitro study, LPA induced expression of several
lymphatic-specific markers (Prox-1, LYVE-1, and podo-
planin) and increased VEGF-C production in blood vas-
cular endothelial cells [human umbilical vein endothelial
cells (HUVECs)].17,18
LPA induces the expression of IL-8 in several types of
cells, including ovarian cancer cells, granulosa-lutein
cells, and HUVECs.19–22 IL-8 has also been shown to
induce proangiogenic responses.23 Several signaling
pathways have been implicated in LPA-induced IL-8 pro-
duction, including a nuclear factor-B (NF-B)-depen-
dent pathway in granulosa-lutein cells20 and Rho kinase
signaling through p38 and JNK activation in HUVECs.22
However, whether LPA has an effect on IL-8 expression in
human LECs is currently unknown.
The objective of the present study was to determine
the effect of LPA on human LECs and lymphangiogenesis
and to elucidate the mechanism underlying LPA effects.
The results of our in vitro and ex vivo investigations reveal
a new role of LPA in promoting lymphangiogenesis in vitro
via up-regulation of IL-8 expression in LECs.
Materials and Methods
Reagents
Lysophosphatidic acid (1-oleoyl-2-hydroxy-sn-glycero-3-
phosphate; 18:1) was purchased from Avanti Polar
Lipids (Alabaster, AL). LPA stock was prepared fresh
before each experiment as 10 mmol/L in PBS and 0.1%
(w/v) charcoal-stripped bovine serum albumin (Sigma-
Aldrich, Munich, Germany). Mouse anti-human IL-8 neu-
tralizing antibody and mouse IgG1 control antibody were
purchased from R&D Systems (Minneapolis, MN). Cal-
cein AM was purchased from Biotium (Hayward, CA).
Cell Culture and Cell Proliferation
Human adult dermal LECs were purchased from Promo-
Cell (Heidelberg, Germany). Three lots of LECs wereused, and all yielded similar results. LECs were cultured
in endothelial growth medium MV2 (EGM-MV2), com-
prised of endothelial basal medium MV2 (EBM-MV2) with
supplement pack (PromoCell). LECs were used between
passages 2 and 5. LECs were made quiescent in a star-
vation medium [EBM-MV2 supplemented with 1% fetal
bovine serum (FBS), 1 g/mL ascorbic acid, and 0.2
g/mL hydrocortisone] for 16 hours before and during
LPA treatment. The serum and supplement concentra-
tions in the starvation medium were chosen to maintain
cell viability. Starvation medium with 5% FBS was used as
positive control for cell proliferation, migration, and tube
formation assays. LECs were treated with 0 to 10 mol/L
LPA, and cell proliferation was first evaluated by tetrazo-
lium salt colorimetric assay (MTS), using a CellTiter 96
AQueous One Solution cell proliferation assay (Promega,
Madison, WI) according to the manufacturer’s instruc-
tions. Proliferation was also examined by cell counting
using a hemocytometer at 72 hours after treatment with 0
to 10 mol/L LPA.
Cell Migration, Scratch Wound, and Tube
Formation Assays
Cell migration was measured using a modified Boyden
chamber assay as described previously.24 Inserts (3-m
pores; BD Discovery Labware, Bedford, MA) were pre-
coated with 1 attachment factor containing gelatin (In-
vitrogen Life Technologies, Carlsbad, CA) before use.
LECs were incubated with treatment or control medium
for 24 hours before seeding into upper chambers and
treated medium was added into lower chambers. Migra-
tion was assessed after staining with Calcein AM by
measuring fluorescence of cells migrated to the lower
chamber using a fluorescence SpectraMax microplate
reader (Molecular Devices, Sunnyvale, CA) from the bot-
tom at 485/535 nm excitation/emission wavelengths. The
migrated cells were identified by the ratio of fluorescence
in LPA-treated LECs compared with non-LPA-treated
controls. Images of the migrated cells in the lower cham-
bers were captured under a Leica DM IL inverted micro-
scope using a digital microscope camera (Optronics,
Goleta, CA).
Scratch wounds were produced in a confluent mono-
layer of LECs. Images of the subsequent LEC migration
process were captured at 30 minutes and at 48 hours.
Wound area was calculated using ImageJ software ver-
sion 1.43t (NIH, Bethesda, MD), as described previ-
ously.25
Tube formation assays were performed and total
tube length was calculated as described previously.24
LECs were treated with or without LPA in starvation
medium for 24 hours before they were seeded on
Matrigel (BD Biosciences, San Jose, CA) in fresh star-
vation medium with or without LPA. Images of the tube
formation process were captured at 6 hours and at 16
hours; total tube length was calculated as described
previously.24
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RNA was isolated using a RiboPure RNA isolation kit
(Ambion, Austin, TX) and was reverse-transcribed using
MMLV reverse transcriptase (Clontech, Mountain View,
CA) according to the manufacturer’s instructions. Gene
expression was quantified using quantitative real-time
PCR (qPCR) on an ABI StepOnePlus system using Taq-
Man gene expression assays with custom TaqMan
probes specific for each gene (Applied Biosystems; Life
Technologies, Foster City, CA). Relative gene expression
was determined and normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) or human -actin
(ACTB). Probes are listed in Table 1.
Nontargeting control or targeted siRNAs (50 nmol/L;
Dharmacon, Lafayette, CO) were transfected with Dhar-
maFECT reagent-1 into LECs according to the manufac-
turer’s instructions. The transfection efficiency of siRNA
was measured by GFP generated by concomitant trans-
fection of GFP-reporter plasmid into LECs. The blocking
effect of siRNA on LECs was monitored by a positive
control GAPDH siRNA in LECs. Gene knockdown was
assessed by qPCR at 24 hours or by enzyme-linked
immunosorbent assay (ELISA) at 48 hours after siRNA
transfection. The effects of LPA on cell growth, survival,
migration, tube formation, and IL-8 expression in LECs
after siRNA treatment were observed at 24 hours after
siRNA transfection.
ELISA
Cell supernatants were collected, and equal amounts of
total protein (3 g) from each well of a 96-well plate were
loaded for measurement of IL-8 level using a human IL-8
ELISA kit II (BD Biosciences) according to the manufactur-
er’s instructions.
Cell supernatants were collected, and equal amounts
of total protein (3 g) were loaded for measurement of
VEGF-A, VEGF-C, VEGF-D, and FGF-2 levels by ELISA
(R&D Systems) according to the manufacturer’s instruc-
tions.
Reporter Constructs and Luciferase Assay
Two firefly luciferase reporter plasmid constructs were
used, one driven by human IL-8 promoter (1481 to 44
bp) (pGL3-IL-8-Luc) versus its control (pGL3-Luc)26,27
and another driven by wild-type human IL-8 promoter
[pGL2-IL-8(wt NF-B)-Luc] versus human IL-8 promoter
Table 1. Probes Used in TaqMan qPCR Assays
Probe Assay ID
Human IL-8 Hs00174103_m1
Human LPA1 Hs00173500_m1
Human LPA2 Hs00173704_m1
Human LPA3 Hs00173857_m1
Human ACTB Hs99999903_m1
Human GAPDH Hs99999905_m1with a mutation at the NF-B binding site [pGL2-IL-8(mut NF-B)-Luc]. Procedures were as described previ-
ously.28,29
LECs were transfected with 200 ng relevant firefly lu-
ciferase reporter plasmids and 2 ng pB-actin-RL Renilla
plasmid (Promega) (transfection efficiency control) using
FuGene HD reagent (Roche, Basel, Switzerland) in 24-
well plates (80% confluency) according to the manufac-
turer’s instructions. After 24 hours, LECs were incubated
with or without 5 and 10 mol/L LPA in starvation medium
for an additional 4 hours. Luciferase/Renilla signals were
then measured using a dual-luciferase reporter assay kit
(Promega).
ChIP Assays
Chromatin immunoprecipitation (ChIP) assays were per-
formed with the ChIP-IT Express kit (Active Motif, Carls-
bad, CA) according to the manufacturer’s instructions.
Briefly, 7  106 LECs were treated with or without 5
mol/L LPA in 150-mm culture dishes for 60 minutes
before cellular proteins and DNA were cross-linked by
1% formaldehyde. Cell lysates were sonicated to gener-
ate DNA fragments from 200 to 1500 bp. Protein G mag-
netic beads with 1 g of either anti-phospho-NF-B p65
(Santa Cruz Biotechnology, Santa Cruz, CA) or anti-IgG
(negative control) were added to the chromatin-containing
supernatants and incubated overnight at 4°C. After reversal
of cross-linking of the protein/DNA complexes to free DNA,
PCR was performed using primers flanking the NF-B bind-
ing site in the IL-8 promoter: 5=-GGGCCATCAGTTG-
CAAATC-3= and 5=-TTCCTTCCGGTGGTTTCTTC-3=.30
Apoptosis Assay
LECs grown to 80% to 90% confluency in four-well cham-
ber slides were treated with serum-free EBM-MV2 me-
dium for 16 hours before being treated with or without
LPA (5 mol/L). Apoptosis was examined by TUNEL as-
say at 36 hours, using the DeadEnd fluorometric TUNEL
system (Promega) or caspase-3 immunostaining at 24
hours using caspase-3 (cleaved) antibody (Biocare Med-
ical, Concord, CA).
Reverse-Phase Protein Array
LECs were treated with 5 mol/L LPA in 30-mm dishes,
and cells were harvested at several time points (0, 5,
10, 20, 30, 45, 60, and 120 minutes) and lysed with
lysis buffer containing 1% Triton X-100, 50 mmol/L
Probe sequence
5=-CAGCTCTGTGTGAAGGTGCAGTTTTGCCAA-3=
5=-CACAGCCCCAGTTCACAGCCATGAATGAAC-3=
5=-TGGTCAAGACTGTTGTCATCATCCTGGGGGC-3=
5=-TGACTGTCTTAGGGGCGTTTGTGGTATGCT-3=
5=-CCTTTGCCGATCCGCCGCCCGTCCACACCC-3=
5=-TATTGGGCGCCTGGTCACCAGGGCTGCTTT-3=HEPES pH 7.4, 150 mmol/L NaCl, 1.5 mmol/L MgCl2, 1
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glycerol, 1 mmol/L Na3VO4, and complete protease
inhibitor cocktail (Roche Diagnostics, Mannheim, Ger-
many). The protein lysates were normalized to a con-
centration of 1 mg/mL, and then denatured in 1% SDS
for 10 minutes at 95°C. Reverse-phase protein array
(RPPA) analysis was performed by staff at the MD
Anderson Functional Proteomics RPPA Core as de-
scribed previously.31,32 A logarithmic value reflecting
the relative amount of each protein in each sample was
generated for analyses.
Western Blotting and IHC
Western blotting was performed as described previ-
ously.33 For IHC of LECs, cells were grown on chamber
slides (Falcon; BD Discovery Labware); for IHC of hu-
man sentinel afferent lymphatic vessels, frozen sec-
tions were fixed in cold acetone. Immunostaining was
then performed as described previously.33 Antibodies
used were rabbit anti-human phospho-NF-B p65
(Ser536) (Cell Signaling Technology, Danvers, MA),
rabbit polyclonal anti-IL-8 (Invitrogen Biosource, Carls-
bad, CA), rabbit anti-human CXCR1/IL8RA (IL-8 recep-
tor  chain) and CXCR2/IL8RB (IL-8 receptor  chain)
antibodies (R&D Systems), rabbit anti-human podopla-
nin (Fitzgerald Industries International, Acton, MA),
mouse anti-Prox-1 (Fitzgerald Industries International),
rabbit anti-human phospho-ERK1/2 (Cell Signaling
Technology), and mouse anti-total ERK1/2 (Cell Signaling
Technology). SYTOX Green (Invitrogen-Molecular Probes,
Carlsbad, CA) was used to visualize cell nuclei. Confocal
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Figure 1. LPA induces LEC proliferation and promotes LEC survival. A: LPA
used as a positive control. B: LPA (5 mol/L) induces LEC proliferation in a tim
manner at 72 hours, relative to no-treatment control. D: LPA reduces LEC apo
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Human Lymphatic Vessel Assay
Small segments (3 to 5 mm) of anatomically confirmed
human sentinel afferent lymphatic vessels were obtained
from patients undergoing intraoperative lymphatic map-
ping and sentinel lymph node biopsy procedures as part
of planned surgical treatment for melanoma under an
Institutional Review Board-approved protocol, as de-
scribed previously.34 Briefly, 1 to 3 mL of 1% isosulfan
blue (Lymphazurin) is injected intradermally around the
tumor or biopsy site immediately before lymphatic map-
ping; the protocol includes intradermal injection of 0.5 to
1 mCi of 99mTc-labeled sulfur colloid 1 to 4 hours before
surgery. Intraoperative localization of the sentinel lymph
nodes is aided by the use of a handheld gamma counter
(Neoprobe 1500 or Neoprobe Neo 2000; Neoprobe, Dub-
lin, OH) and visualization of the blue dye in lymphatic
vessels and sentinel lymph nodes. Tiny segments of hu-
man afferent lymphatic vessels attached to the sentinel
lymph node were harvested. Sentinel afferent lymphatic
vessels were placed in cold EGM-MV2 medium with 10%
FBS, transported immediately to the laboratory on wet
ice, carefully dissected to remove perilymphatic tissues
under a dissecting microscope, and then cut lengthwise
to expose the luminal surface. To ensure adequate ex-
perimental controls, each vessel segment was tran-
sected into two subsegments. Each pair of open vessel
subsegments were cultured in two separate wells sup-
plemented with EGM-MV2 medium and 20% FBS con-
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AJP May 2012, Vol. 180, No. 5taining antibiotics for 16 hours before treatment with or
without 10 mol/L LPA with 10% FBS and antibiotics for
an additional 24 hours. Each vessel segment was em-
bedded in optimal cutting temperature compound (OCT;
Sakura Finetek, Torrance, CA) for frozen section prepa-
ration and IHC. For the present study, a total of four
vessels from two patients were used.
Statistical Analysis
Student’s t-test was used to evaluate the data. Data are
expressed as means  SEM. P values of 0.05 were
considered statistically significant.
Results
LPA Promotes LEC Proliferation, Survival,
Migration, and Tube Formation
Lymphatic endothelial cell lineage was confirmed for
LECs used in the present study by immunohistochemical
analysis. The LECs used (passages 2 to 5) all expressed
the lymphatic endothelial cell markers podoplanin and
Prox-1 and the panendothelial cell marker CD31, and did
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CD34 (see Supplemental Figure S1 at http://ajp.
amjpathol.org). As expected, HUVECs expressed both
CD31 and CD34, but did not express podoplanin or
Prox-1. LPA induced a dose- and time-dependent in-
crease in the proliferation of LECs (Figure 1, A and B) and
a dose-dependent increase in the number of LECs (Fig-
ure 1C). We next tested the effect of LPA on LEC survival.
LPA (5 mol/L) reduced apoptosis of LECs induced by
serum starvation as measured by TUNEL assay and
cleaved caspase-3 immunohistochemical staining (Fig-
ure 1D). Taken together, these data demonstrate that
LPA induces LEC proliferation and promotes LEC survival
in vitro.
LPA treatment significantly increased LEC migration in
a dose- and time-dependent manner, as measured by
both a modified Boyden chamber assay (Figure 2, A and
B) and a scratch wound assay (Figure 2C). We next
assessed whether LPA induces formation of tube-like
networks by LECs in Matrigel. LPA promoted LECs to
form tube-like networks, compared with non-LPA-treated
controls (Figure 2D). Together with the observed effects
on growth and survival, these data provide evidence that
LPA promotes behaviors of LECs that are essential for
lymphangiogenesis in vitro.
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LPA is known to induce IL-8 in several cell types. Be-
cause IL-8 has been shown to induce proangiogenic
responses, we sought to investigate the possible effect of
IL-8 in LPA-treated LECs. We found that LPA treatment
resulted in a dose-dependent increase in IL-8 secretion
by LECs in vitro, as determined by ELISA (Figure 3A).
qPCR demonstrated that LPA increased IL-8 mRNA ex-
pression in LECs in a dose- and time-dependent manner
(Figure 3, B and C).
LPA induced IL-8 promoter-driven luciferase activity in
LECs in a dose-dependent manner, by 2.5-fold (Figure
3D). These data indicate that LPA up-regulates the tran-
scription and secretion of IL-8 in LECs.
VEGF-A, VEGF-C, VEGF-D, and FGF-2 are known to
induce lymphangiogenesis.13 To examine the potential
role of these known lymphangiogenic factors, we exam-
ined their expression in LECs in culture after LPA treat-
ment. Importantly, none of these lymphangiogenic fac-
tors were induced by LPA treatment as evaluated by
ELISA (data not shown), which supports the notion that
none of these factors are significantly involved in LPA-
induced lymphangiogenesis in vitro.
IL-8 Plays an Important Role in LPA-Induced
Lymphangiogenesis in Vitro
To explore the significance of LPA-induced up-regulation
of IL-8 in LECs, we silenced IL-8 expression in LECs by
siRNA. The transfection efficiency of siRNA was 90%, as
measured by GFP generated by concomitant transfection
of GFP-reporter plasmid into LECs. GAPDH siRNA
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Figure 3. LPA induces IL-8 expression in LECs. A: IL-8 protein levels in LEC
supernatants as examined by ELISA at 72 hours. B: IL-8 mRNA levels at 4 hours,
as examined by qPCR. C: LPA-induced IL-8 mRNA expression in LECs peaks at
4 hours. D: LPA-induced increases in luciferase (Luc) activity are driven by IL-8
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treated LECs with non-LPA-treated controls. *P  0.05, **P  0.01.served as a positive control and reduced up to 81% ofGAPDH RNA expression (data not shown). Both LPA-
induced and endogenous IL-8 expression were signifi-
cantly inhibited by IL-8 siRNA in LECs at the protein level
as determined by ELISA (see Supplemental Figure S2A
at http://ajp.amjpathol.org). Suppression of IL-8 expres-
sion in LECs inhibited the LPA-induced increase in LEC
proliferation (Figure 4A), survival (Figure 4B), migration
(Figure 4C), and tube formation (Figure 4D), compared
with control cells transfected with nontargeting siRNA.
IL-8 neutralizing antibody also blocked LPA-induced cell
proliferation, survival, migration, and tube formation (see
Supplemental Figure S2, B–E, at http://ajp.amjpathol.org).
Importantly, both of the IL-8 receptors (CXCR1 and
CXCR2) were expressed in cultured LECs (see Supple-
mental Figure S2F at http://ajp.amjpathol.org). Taken to-
gether, these data support a significant functional role for
IL-8 in LPA-induced lymphangiogenesis in LECs in vitro.
NF-B Is Activated by LPA in LECs and Is
Critical to IL-8 Induction
To better understand the mechanism underlying LPA-in-
duced lymphangiogenesis in vitro, we examined the expres-
sion of total and activation-specific protein markers in ki-
nase signaling pathways in LECs using RPPAs. LPA
treatment markedly and rapidly affected the expression of a
large number of proteins and phospho-proteins (Figure 5A).
Clustering analysis identified coordinated up-regulation of
multiple activation-specific markers in the PI3K-AKT path-
way, including p-AKT (Ser473), p-GSK-3/ (Ser21/9), p-
PDK1 (Ser241), and p-TSC2 (Thr1462); this analysis also
revealed marked increase in components of other kinase
cascades, including p-MAPK, p-p38-MAPK, p-JNK, p-S6,
and p-SMAD5 (Figure 5A).
Quantitative analysis of the RPPA data revealed that
the protein that was increased from baseline more than
any other marker at both 60 minutes (11.3-fold versus
baseline) and 120 minutes (9.2-fold) was p-NF-B
(p65 subunit) (see Supplemental Table S1 at http://ajp.
amjpathol.org). Western blot analysis confirmed the ob-
served increase in p-NF-B p65 levels, which was noted
as soon as 20 minutes and peaked at 60 minutes after
LPA treatment (Figure 5B). Activation of NF-B was also
confirmed by IHC; p-NF-B p65 was highly expressed in
the nuclei of LPA-treated LECs 60 minutes after LPA
treatment, but not in untreated controls (see Supplemen-
tal Figure S3 at http://ajp.amjpathol.org).
Previous studies have demonstrated that NF-B regu-
lates LPA-induced increases in IL-8 in some, but not all,
cell types.20,22 On the basis of our observation that LPA
induced NF-B activation in LECs, we tested the hypoth-
esis that NF-B directly mediates the observed LPA-in-
duced increase in IL-8 transcription. To examine whether
LPA-activated p-NF-B p65 binds directly to the NF-B
binding site in the IL-8 promoter in LECs, we performed a
ChIP assay using p-NF-B p65 antibody. Indeed, ChIP
assay confirmed that p-NF-B p65 bound to the NF-B
binding site in the IL-8 promoter in LPA-treated LECs, but
not in untreated controls (Figure 5C). To further test
whether NF-B binding to the IL-8 promoter is required
2176 Mu et al
AJP May 2012, Vol. 180, No. 5for IL-8 induction, we transfected LECs with either a
firefly luciferase reporter construct containing the wild-
type IL-8 promoter or the same promoter containing a
mutation at the NF-B binding site.28,29 Transfection of
cells with the promoter containing the mutation abol-
ished LPA-induced IL-8 promoter-driven luciferase ac-
tivity (Figure 5D). Together, these data support the
hypothesis that LPA up-regulates IL-8 production by
activating the NF-B pathway.
LPA2 Is a Critical Mediator of LPA Effects on
LECs
The biological activity of LPA is mediated by interaction of
LPA with its receptors, the best characterized of which
are LPA1, LPA2, and LPA3. Because specific antibodies
against LPA1–3 receptors are lacking, the expression of
these receptors was examined by qPCR. We demon-
strated that these receptors are all expressed in LECs
(see Supplemental Figure S4A at http://ajp.amjpathol.
org). To determine which of these LPA receptors are
involved in the effect of LPA on LECs, we used siRNA to
individually silence each LPA receptor. Each LPA recep-
tor subtype siRNA treatment significantly decreased LPA
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Having demonstrated knockdown efficiency and LPA
receptor specificity for the different siRNAs, we then
tested their respective influence on the effects of LPA on
LECs. LPA2 siRNA significantly blocked LPA-induced
IL-8 up-regulation in LECs, compared with nontargeting
siRNA. In contrast, neither LPA1 nor LPA3 siRNA abro-
gated LPA-induced IL-8 activity (Figure 6A). LPA-acti-
vated p-NF-B p65 was blocked by LPA2 siRNA in LECs
at 60 minutes, compared with nontargeting siRNA, but
not by LPA1 or LPA3 siRNA (Figure 6B). Further experi-
ments demonstrated that LPA2 siRNA also inhibited LPA-
induced increases in cell proliferation (Figure 6C) and
migration (Figure 6D), cell survival (Figure 4B), and tube
formation (Figure 6E). These data support the hypothesis
that LPA2 is critical to mediating the effects of LPA on
LECs.
LPA Induces IL-8 Expression in Luminal LECs of
Human Sentinel Afferent Lymphatic Vessel
Explants
To corroborate these findings and determine the effect of
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Figure 4. IL-8 plays an essential role in LPA-
induced lymphangiogenesis in vitro. A: IL-8
siRNA partially blocks LPA-induced LEC prolifer-
ation, as examined by MTS assay at 24 hours. B:
IL-8 siRNA and LPA2 siRNA partially blocks LPA-
induced LEC survival by cleaved caspase-3, as
examined by IHC at 24 hours (green; nuclei stain
blue). C: IL-8 siRNA partially blocks LPA-induced
LEC migration at 24 hours. D: IL-8 siRNA partially
blocks LPA-induced capillary-like tube formation
of LECs on Matrigel at 16 hours. Scale bar  50
m. Original magnification: 20 (B); 10 (D).
Relative values compare LPA-treated LECs with
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controls. Data are expressed as means SEM. *P
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tients undergoing planned lymphatic mapping surgery
(Figure 7A) and sectioned them to expose the luminal
surface to either LPA or no treatment ex vivo (Figure 7B).
To document their lymphatic lineage, we confirmed that
these human afferent lymphatic vessels expressed the
lymphatic-specific markers podoplanin and Prox-1 (see
Supplemental Figure S5 at http://ajp.amjpathol.org). LPA
increased IL-8 expression in the LECs of lymphatic ves-
sel endothelia in LPA-treated subsegments, compared
with matched non-LPA-treated control subsegments from
the same lymphatic vessel specimens (Figure 7C). LPA-
induced IL-8 expression was indeed observed in each of
four lymphatic vessel harvested from two patients. Addi-
tionally, the IL-8 receptors CXCR1 and CXCR2 were both
expressed in lymphatic vessel endothelia (see Supple-
mental Figure S6 at http://ajp.amjpathol.org); LPA treat-
ment did not alter their expression (data not shown).
Together, these data provide further evidence that LPA
induces IL-8 expression in LECs in human lymphatic
vessel endothelia explants, suggesting a potential role of
LPA in IL-8 production and lymphangiogenesis in vivo.
Discussion
In the present study, we demonstrated that LPA, a bio-
active phospholipid produced by many different tumor
A
50 10 20 30 45 60 120
B
-actin
time (minutes)
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
50 10 20 30 45 60 120
time (minutes)
D
en
si
to
m
et
ry
 (f
ol
d)
0
1
2
3
4
5
Inp
IgG
LPA
C
Fo
ld
 in
pu
t
-
-
-
*
Figure 5. NF-B is activated by LPA in LECs and is critical to IL-8 induction.
p65) after LPA treatment (asterisk). Red indicates high phosphoprotein leve
by 5 mol/L LPA as examined by Western blot. C: LPA-activated p-NF-B p65
is relative to control input. D: Mutation of the NF-B binding site in the IL-8 p
SEM. Relative values compare LPA-treated LECs with non-LPA-treated contrcells, promotes lymphangiogenesis in vitro and up-regu-lates IL-8 expression in LECs via the LPA receptor LPA2.
Indeed, LPA induced dose- and time-dependent in-
creases in LEC proliferation, migration, and IL-8 produc-
tion, each of which was abrogated by LPA2 siRNA. We
also demonstrated that LPA regulates IL-8 expression via
the NF-B pathway. Finally, we corroborated our findings
in human lymphatic vessels in situ by demonstrating that
LPA up-regulates IL-8 production in the luminal LECs of
intact human sentinel afferent lymphatic vessel explants.
Tumor-associated lymphatic vessels act in part as a
conduit by which tumor cells can disseminate to regional
lymph nodes and potentially to distant sites.10 Tumors
interact with the lymphatic vasculature in many ways,
including vessel co-option, chemotactic migration and
invasion into lymphatic vessels, and induction of lymp-
hangiogenesis. Tumor-induced lymphangiogenesis has
been correlatively and functionally associated with me-
tastasis formation and poor prognosis in multiple types of
cancer. In preclinical models, experimental blockade of
tumor-induced lymphangiogenesis inhibited metastasis
formation in lymph nodes and often in other organs,
which suggests that lymphatic blockade might suppress
metastasis formation.35
LPA is a bioactive phospholipid that is produced by
activated platelets, leukocytes, epithelial cells, adi-
pocytes, peritoneal mesothelial cells, fibroblasts, and tu-
mor cells.36 LPA circulates in normal human peripheral
IP
**
- + - +
+ + - -
- - + +
0
0.5
1
1.5
2
2.5
3
R
el
at
iv
e 
lu
ci
fe
ra
se
*
D
pGL2-IL-8-Luc plasmid type
Control (no LPA)
LPA (5 mol/L
red heat map of results of RPPA analysis. Note activation of NF-B (p-NF-B
e to black or green. B: Activation of NF-B (p-NF-B p65) pathway in LECs
endogenous IL-8 promoter in LECs as examined by ChIP assay. Fold change
r blocks LPA-induced IL-8 promoter activity. Data are expressed as means 
0.05, **P  0.01.ut
+
-
-
A: Cluste
ls relativ
binds toblood at plasma concentrations of 100 nmol/L.6,37,38
s2178 Mu et al
AJP May 2012, Vol. 180, No. 5However, LPA levels have been reported to be increased
in 90% of ovarian cancer patients6 and in at least some
patients with myeloma, endometrial cancer, and cervical
cancer.6,7 Macrophage-induced lymphangiogenesis has
been shown to directly induce ascites in a murine model
of ovarian cancer.12 Because massive ascites formation
is a major cause of morbidity and mortality in patients with
ovarian cancer,12 and LPA is known to be secreted by
ovarian cancer cells, our finding that LPA induces lymp-
hangiogenesis in vitro sheds light on the mechanisms
associated with ascites formation in ovarian cancer pa-
tients and suggests that LPA may be a therapeutic target
in cancer patients. In vitro studies have shown that LPA
induces proliferation and migration in both human blood
vascular endothelial cells and endometrial carcinoma
cells at LPA concentrations of 1 to 10 mol/L.17,39 In the
present study, LPA induced lymphangiogenesis in LECs
in vitro at similar LPA concentrations (2.5 to 10 mol/L;
maximal effect at 5 mol/L). Recent data support the
notion that extracellular ATX, responsible for production
of LPA, can associate directly with the cell surface and
thus could potentially generate the high local concentra-
tions required for cellular effects without necessarily in-
creasing the circulating LPA concentration.40 Overall, a
better understanding of molecular pathways that regulate
lymphangiogenesis may reveal ways to interfere with me-
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LPA (5 mol/L)tastasis.Blood and lymphatic vessels represent two important
constituents of the tumor microenvironment and the met-
astatic cascade.41 Although LPA has previously been
reported to induce angiogenesis20 and contribute to me-
tastasis,42 to our knowledge the present study is the first
to directly explore the potential role of LPA in lymphan-
giogenesis in vitro. In the present study, LPA functionally
contributed to lymphangiogenesis in vitro, as evidenced
by dose- and time-dependent increases in LEC prolifer-
ation, migration, and tube formation (Figures 1 and 2).
Serum IL-8 levels are increased in many cancer pa-
tients, and such increases have been shown to correlate
with angiogenesis, tumorigenicity, and metastatic poten-
tial in several murine models of human cancer.43–45 Al-
though LPA is reported to induce IL-8 expression in sev-
eral cell types, including blood vascular endothelial
cells,21 the effects of LPA and IL-8 on LECs have not
previously been explored. We show here that LPA in-
duces IL-8 expression in LECs. Indeed, we found that
LPA up-regulated IL-8 expression in LECs at both tran-
scriptional and protein levels (Figure 3, A–C) and further
confirmed this finding by demonstrating that LPA in-
creased IL-8 expression in the luminal LECs of human
sentinel afferent lymphatic vessels ex vivo (Figure 7C).
The present study shows that IL-8 siRNA partially abro-
gates LPA-induced lymphangiogenesis in vitro (Figure 4),
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Both CXCR1 and CXCR2 were expressed in LECs in vitro
(see Supplemental Figure S2F at http://ajp.amjpathol.org),
and is consistent with previous reports.46 Overall, the
presence of IL-8 receptors on human lymphatic vessel
LECs (see Supplemental Figure S6 at http://ajp.
amjpathol.org) supports a possible direct effect of IL-8
on lymphangiogenesis in vitro. Additional studies are
needed to further elucidate how IL-8 induction contrib-
utes to the effect of LPA on lymphangiogenesis in vitro.
Several signaling pathways have been reported to me-
diate LPA-induced IL-8 production. The NF-B pathway
has been implicated in various cell types, including bron-
chial epithelial cells47 and granulosa-lutein cells.20 In
contrast, rho kinase signaling has been shown to mediate
LPA-induced IL-8 production in HUVECs through p38
and JNK activation, independent of NF-B.22 In the pres-
ent study, RPPA analysis demonstrated marked induction
of activation-specific markers in these and other path-
ways (Figure 5A). We chose to focus on activation of
NF-B, because its phosphorylation was increased more
than that of any other protein in the present study. The
induction of NF-B activation was confirmed by both
Western blotting and IHC. ChIP assay further revealed
that LPA-activated p-NF-B p65 bound to an NF-B bind-
ing region in the IL-8 promoter in LPA-treated LECs, an
observation supported by the time sequence of activation
of p-NF-B p65 (peak at 60 minutes) and increase in IL-8
transcription (peak at 4 hours) after LPA treatment in
LECs. Furthermore, inhibition of NF-B binding by a mu-
tation of the NF-B binding region in the IL-8 promoter
abolished LPA-induced IL-8 promoter activity, further
supporting the contention that LPA regulates IL-8 tran-
scription via the NF-B pathway. These data strongly
support a critical functional role for NF-B in the regula-
Sentinel 
lymph node
Afferent 
lymphatic 
vessel
A
Control (no LPA) 
B
Figure 7. LPA induces IL-8 expression in luminal
LECs of human sentinel afferent lymphatic vessel ex-
plants. A: Intraoperative identification and harvest of
human sentinel afferent lymphatic vessels.B:Human
sentinel afferent lymphatic vessels were isolated, pre-
pared ex vivo, and treated with or without LPA
(10 mol/L) for 24 hours. The background grid is
1 mm 1 mm. C: Confocal imaging of IL-8 expres-
sion (red) in LECs of human afferent lymphatic ves-
sels by IHC; nuclei stain green (SYTOXGreen). H&E
staining of the human lymphatic vessels is shown for
comparison. Scale bar  10 m. Asterisks indicate
luminal side of lymphatic vessels; arrows indicate
LECsof the lymphatic vessels. (PanelA image: Copy-
right retained by J.E.G. and theMDAnderson Cancer
Center. Reprinted with permission.)tion of IL-8 production. It is clear from the RPPA experi-ment that LPA induced the activation of multiple kinase
signaling pathways (ie, PI3K-AKT, MAPK). Importantly,
the lack of induction in LECs of other known prolymphan-
giogenic factors (VEGF-A, VEGF-C, VEGF-D, and FGF-2)
by LPA in our studies further supports an important role
for LPA in the LPA/IL-8/NF-B axis and a minimal role for
these other growth factors. Planned studies in our re-
search group to interrogate the functional role of these
signaling pathways, and their possible interactions with
NF-B signaling, should further refine understanding of
the signaling pathways involved in the effect of LPA on
LECs and on the regulation of IL-8.
Most biological functions of LPA have thus far been
shown to be mediated through interaction with the LPA
receptors LPA1, LPA2, and LPA3.
2 LPA2 has been re-
ported to play important roles in tumorigenesis and me-
tastasis in both clinical and experimental studies; in at
least one study in patients with gastric cancer, LPA2
expression correlated with invasion and metastasis.8
Moreover, in a murine model of mammary carcinoma,
overexpression of LPA2 in mice was associated with a
higher incidence and earlier development of mammary
carcinoma than that of either LPA1 or LPA3.
48 In contrast,
the absence of LPA2 attenuated tumor formation in an
experimental murine model of colitis-associated colon
adenocarcinoma.49 LPA2 has also been shown to medi-
ate LPA-induced activation of growth-regulated onco-
gene  (GRO-) in ovarian cancer cells and contribute to
both angiogenesis and tumorigenesis.50 In the present
study, we found that LPA1, LPA2, and LPA3 were all
expressed in LECs; however, only LPA2 siRNA blocked
LPA-induced IL-8 production (Figure 6A) and LPA acti-
vation of p-NF-B p65 (Figure 6B). LPA2 siRNA also
blocked LPA-induced LEC proliferation and migration
(Figure 6, C and D), cell survival (Figure 4B), and tube
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AJP May 2012, Vol. 180, No. 5that LPA induces lymphangiogenesis in vitro and IL-8
production via interaction with LPA2 in LECs and are
consistent with the observation by others that LPA2 is
involved in tumor progression and metastasis.8,49 Lym-
phangiogenesis is also essential for lymphatic vessel
system development. However, studies on LPA1–3 knock-
out mice did not reveal cardiovascular developmental
defects.51–54 Further evaluation of the LPA1–3-null mice
for lymphatic vascular defects will help to elucidate the
role of LPA1–3 in lymphangiogenesis.
54
Our present study demonstrates that LPA induces lym-
phangiogenesis in LECs in vitro. We recognize that, al-
though not all steps of lymphatic vessel formation in vivo
are recapitulated using LECs in culture, numerous rele-
vant processes can be explored, including cell prolifera-
tion, apoptosis, migration (determined by wound scratch
assay or Boyden chamber assay), and morphogenesis
(ie, tubulogenesis); these lymphatic endothelial cellular
functions collectively contribute to lymphatic vessel for-
mation,55,56 and have been widely used to analyze lym-
phangiogenesis in vitro.55–62 We extended these obser-
vations using human afferent lymphatic vessel explants
(a truly unique resource) and also demonstrated LPA-
induced IL-8 production in the LECs of these human
lymphatic vessels (Figure 7, A–C). Additional studies on
LPA and its receptors in lymphatic endothelium in vivo will
likely further refine our understanding of lymphangiogen-
esis in vivo.
In the present study, we demonstrated for what we
believe is the first time that LPA increases human LEC
proliferation, survival, migration, and tube formation, pro-
motes lymphangiogenesis in vitro via interaction with
LPA2, and up-regulates IL-8 production in LECs via an
NF-B-mediated pathway. We also corroborated our find-
ings by demonstrating that LPA up-regulates IL-8 pro-
duction in the luminal LECs of human sentinel afferent
lymphatic vessels ex vivo. Overall, these data shed
considerable light on the links among LPA, IL-8, and
lymphangiogenesis, advance our understanding of the
role of LPA in tumor progression and metastasis, and
strongly support accumulating evidence that LPA may
serve as a therapeutic target in cancer patients.
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